Key Overactive Bladder Treatment Market Players:
- Bayer AG
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Pfizer Inc.
- Allergan plc / AbbVie Inc.
- Teva Pharmaceutical Industries Ltd.
- Medtronic plc
- Endo International plc
- Urovant Sciences
- Sanofi S.A.
- Johnson & Johnson (Janssen)
- Aurobindo Pharma Ltd.
- Dr. Reddy’s Laboratories Ltd.
- Sun Pharmaceutical Industries Ltd.
- Viatris Inc.
- Mylan N.V.
- AbbVie (merged with Allergan)
The global OAB treatment market is highly competitive. Astellas, Pfizer, Allergan, and AbbVie dominate this market via flagship drugs such as Myrbetriq (mirabegron) and Vesicare, generics from Teva, and also neuromodulation devices marketed by Medtronic. In the competitive landscape, the new entrants from Japan, Sumitomo/Urovant with Gemtesa, Hisamitsu with OABLOK patch, and local manufacturers are developing diversified innovations into non-oral routes and device therapies. Indian generics companies such as Aurobindo, Dr. Reddy's Laboratories, and Sun Pharma reinforce the market on affordability and accessibility in emerging regions.
Here is a list of key players operating in the global market:
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of the overactive bladder treatment market is estimated to reach approximately USD 4.5 billion.
The market size for the overactive bladder treatment market is projected to reach around USD 7 billion by the end of 2035, rising at a CAGR of about 5.1% during the forecast period (2026-2035).
The major players in the global market are Bayer AG, Pfizer Inc., Allergan plc / AbbVie Inc., Teva Pharmaceutical Industries Ltd., and others.
In terms of patient age group, adults (≥18 years) are anticipated to dominate with almost 85% of the market share by 2035.
The market in North America is expected to continue dominating the forecast period, accounting for a significant share of approximately 41%.
